期刊文献+

PPARγ基因C161T多态性与中国汉族人动脉粥样硬化血栓形成性梗死的相关性

Conelafion between PPART CI61T polynwphisrm mid atherothronlmtic infraction in a Chinese Han population
原文传递
导出
摘要 目的探讨中国汉族人群过氧化物酶体增殖物激活受体γ(peroxisome proliferator—activated receptor γ,PPAR-γ)基因C161T多态性与动脉粥样硬化血栓形成性脑梗死(atherothrombotic infarction,ATI)的关系。方法纳入ATI患者(ATI组)和同期无卒中、短暂性脑缺血发作和心肌梗死史的体检者(对照组),采用聚合酶链反应一限制性片段长度多态性方法检测PPAR~基因C161T基因型,比较ATI组与对照组基因型和等位基因频率。结果共纳入ATI患者112例和对照者112例。ATI组年龄[(67.9±11.73)岁对(66.5±10.35)岁;t=0.386,P=0.701]和男性的构成比(61.61%对58.04%;y。=0.297,P=0.586)与对照组无显著性差异。ATI组高血压(59.82%对44.62%;Y。=5.171,P=0.023)和2型糖尿病(26.79%对9.82%;矿=10.778,P:0.001)患者构成比以及体质指数[(25.13±1.86)kj对(24.11±1.81)k耐;卢3.543,P=0.001]、收缩压[(158.84±20.15)millHg对(135.82±19.58)millHg,1FilmHg=0.133kPa;扣7.350,P=0.000]、舒张压[(76.90±13.64)rnlTlHg对(68.90±8.52)millHg;户4.374,P=0.000]和空腹血糖[(6.523±2.831)mmol/L对(5.706±2.177)mmol/L;卢2.026,P=0.044]均显著性高于对照组。ATI组CC、CT和TT基因型频率分别为77.7%、17.0%和5.4%,对照组分别为69.6%、22.3%和8.O%,两组间无显著性差异(X2=1.909,P=0.385)。ATI组C和T等位基因频率分别为86.2%和13.8%,对照组分别为80.8%和19.2%,两组间亦无显著性差异(矿=2.331,P=0.127)。结论中国汉族人群PPAR',/基因C161T多态性可能与ATI发病无关。 Objective To investigate the relationship between the C161T polymorphisms in peroxisome proliferators-aetivated receptor 5' (PPAR/) lae and atherothrombotic infarction (ATI) in a Chinese Han population. Methods The patients with atherothrombotic infarction and controls, who without histories of stroke, transient ischemic attack and myocardial infarction were enrolled. Genotypes of the PPAR/ C161T polymorphisms were determined using the polymerase chain reaction-restriction fragment length polymorphism. The frequencies of notype and allele in patients with ATI and controls were compared. Results A total of 112 ATI patients and 112 controls were enrolled. There were no significant differences in the age (67. 9± 11.73 years vs. 66. 5 ± 10. 35 years; t =0. 386, P =0. 701) and the proportion of male (61.61% vs. 58. 04% ; X2 =0. 297, P =0. 586) in the ATI group and the control group. The proportions of hypertension (59. 82% vs. 44. 62% ; X2 = 5. 171, P = 0. 023), type 2 diabetes mellitus (26. 79% vs. 9. 82% ; X2 = 10. 778, P = 0. 001 ) in the ATI goup were significantly higher than those in the control group. Body mass index (25. 13± 1.86 kg/m2 vs. 24. 11 ± 1.81 kg/m2; t = 3. 543, P= 0. 001), systolic pressure (158.84 ± 20. 15 rnm Hgvs. 135.82 ± 19. 58 mm Hg; t = 7. 350, P = 0. 000), diastolic pressure (76. 90 ± 13.64 mm Hgvs. 68. 90 ±8. 52 mm Hg; t =4. 374, P =0. 000) and the level of fasting blood glucose (6. 523 ±2. 831 mmol/L vs. 5. 706 ± 2. 177 mmol/L; t =2. 026, P = 0. 044) in the ATI group were significantly higher than those in the control group. The genotype frequencies of CC, CT and TT in the ATI group were 77. 7%, 17. 0% and 5.4%, respectively, and in the control group were 69.6%, 22. 3% and 8.0%, respectively. There were no siificant difference between the two groups 0(2 = 1. 909, P =0. 385). The allele frequencies of C and T in the ATI group were 86. 2% and 13.8%, respectively, and in the control group were 80. 8% and 19. 2%, respectively. There were no significant difference between the two groups x2 =2. 331, P=0. 127). Conclusions PPAR C161T polymorphisms may be not associated with the onset of ATI in a Chinese Ham population.
出处 《国际脑血管病杂志》 北大核心 2013年第5期353-356,共4页 International Journal of Cerebrovascular Diseases
关键词 卒中 脑梗死 过氧化物酶体增生物激活受体1 多态现象 遗传学 动脉粥样硬化 险因素 Stroke Cerebral Infarction PPAR gamma Polymorphism, Genetic Atherosclerosis RiskFactors
  • 相关文献

参考文献20

  • 1Rosamond W, Flegil K, Furie K, et aI; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics- 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, 117: e25-el46.
  • 2Deeb SS, Fajas L, Nemoto M, et aI. A Prol2Ala substitution in PP ARy2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 1998, 20: 284-287.
  • 3Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel ill).JAMA, 2001, 285: 2486- 2497.
  • 4Fong WH, Tsai HD, Chen YC, et al. Anti-apoptotic actions of PPAR-'Y against ischemic stroke. Mol Neurobiol, 2010, 41: 180-186.
  • 5Sa1adin R, Fllias L, Dana S, et aI. Differential regulation of peroxisome proliferator activated receptor 'Y I (PP AR'Y I) and PP AR'Y2 rressenger RNA expression in the early stages of adipogenesis, Cell Growth Differ, 1999, 10: 43-48.
  • 6Verrier E, Wang L, Wadham C, et aI. PPAR'Y agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacy lglycerol kinase. Cire Res, 2004,94: 1515-1522.
  • 7Law RE, Meehan WP, Xi XP, et aI. Trogiitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.J Clin Invest, 1996,98: 1897-1905.
  • 8Marx N, Sukhova GK, Collins T, et aI. PPARa activators inhibit cytokine-indueed vascular cell adhesion molecule-I expression in human endothelial cells. Circulation. 1999,99: 3125-3131.
  • 9Rodngucz-Esparragon FJ, Rodriguez-PerezJC, Macias-Reyes A. et aI. Peroxisome proliferator-activated receotor-vz-Prol zAla and endothelial nitric oxide synthase-aa/bgne polymorphisms are associated with essential hypertension.J Hypertens, 2003, 21: 1649-1655.
  • 10Ostgren CJ, Lindblad U, Melander 0, et aI. Peroxisome proliferator?activated receptor-y Prol2Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project.J Hypertens, 2003, 21: 1657-1662.

共引文献829

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部